Hub : Traits :

Mean time to correctly identify matches

312 significantly associated models · 76 unique genes.

Significant Loci

# chr p0 p1 # assoc genes # joint genes best TWAS P best SNP P cond SNP P % var exp joint genes
1 1 96492298 97978299 1 1 2.2e-07 3.3e-06 1.5e-02 72 PTBP2
2 1 204982713 206329620 5 1 3.2e-11 6.7e-10 3.4e-01 98 PM20D1
3 2 23729232 25278723 2 1 5.7e-08 2.6e-08 1.0e+00 100 AC009228.1
4 2 200473658 202044716 1 1 7.3e-09 9.4e-10 1.4e-02 84 SPATS2L
5 3 46365783 48077701 2 1 2.2e-07 8.1e-08 2.6e-02 83 SETD2
6 5 111499732 112950045 6 1 1.2e-10 2.0e-10 8.9e-02 93 REEP5
7 5 138933151 140423473 2 1 4.4e-11 2.0e-11 1.1e-01 94 PFDN1
8 6 97341715 97979053 1 1 1.0e-07 9.8e-06 2.4e-03 53 C6orf167
9 6 108183628 109704062 1 1 4.2e-09 4.4e-11 2.6e-03 79 FOXO3
10 7 44090853 45498400 1 1 1.1e-07 1.4e-08 1.2e-02 80 ZMIZ2
11 7 122978928 124733550 1 1 3.8e-08 3.7e-09 2.4e-04 61 RP5-921G16.1
12 9 85899677 87315117 2 1 8.8e-12 6.7e-11 4.8e-01 99 RMI1
13 10 12239118 13839729 1 1 4.0e-08 1.1e-04 1.2e-01 84 CCDC3
14 10 14555086 16102103 1 1 1.3e-07 2.1e-07 1.0e-01 90 FAM171A1
15 11 30764890 32226445 1 1 1.4e-07 4.3e-06 7.7e-06 5 IMMP1L
16 11 45258966 48285906 14 1 4.6e-13 2.7e-11 3.2e-02 90 ARHGAP1
17 11 63295034 64687797 1 1 1.8e-07 5.4e-07 1.0e+00 100 TRPT1
18 12 48605088 50199949 6 1 5.2e-12 4.2e-13 4.3e-03 84 CCDC65
19 12 111154626 113517494 12 1 3.2e-12 2.1e-11 6.5e-02 92 SH2B3
20 17 6907070 7410212 1 1 2.7e-07 1.6e-07 9.9e-08 -3 C17orf81
21 17 43871147 45510971 8 2 3.0e-24 1.2e-19 8.5e-01 100 ARL17A KANSL1
22 17 75309351 76804316 2 1 1.3e-08 1.5e-07 8.4e-01 100 AC021593.1
23 18 33665455 35103667 1 1 7.6e-08 3.9e-10 7.0e-04 71 TPGS2
24 19 3309021 4735663 1 1 8.0e-08 1.8e-10 1.6e-04 65 PIAS4
25 20 46840115 48410403 2 1 4.7e-08 3.8e-07 2.0e-01 94 ARFGEF2

Pleiotropic Associations

Trait chisq ratio # genes+ # genes++ % genes++ corr corr P genes
Bipolar Disorder (2018) 1.99 1 0 0.0 0.00 1.0e+00 SPATS2L
Bipolar Disorder or Schizophrenia 2.01 2 0 0.0 0.00 1.0e+00 ARHGAP1 SPATS2L
Depressed Affect (Nagel 2018) 1.94 2 0 0.0 0.00 1.0e+00 ARHGAP1 SH2B3
Depression (Nagel 2018) 2.09 2 0 0.0 0.00 1.0e+00 ARFGEF2 ARHGAP1
Intelligence (Savage-Jansen 2018) 4.22 8 4 8.9 0.25 5.5e-01 ARFGEF2 ARHGAP1 ARL17A CCDC65 FOXO3 PFDN1 PIAS4 RMI1
Neuroticism (Nagel 2018) 1.94 3 0 0.0 0.00 1.0e+00 ARHGAP1 ARL17A KANSL1
Schizophrenia (2018) 1.89 1 0 0.0 0.00 1.0e+00 ARHGAP1
Schizophrenia vs Biploar Disorder 2.54 2 0 0.0 0.00 1.0e+00 ARFGEF2 ARHGAP1
Worry (Nagel 2018) 2.27 3 0 0.0 0.00 1.0e+00 ARL17A FOXO3 RMI1
Reaction Time 18.68 26 18 40.0 1.00 4.4e-27 AC009228.1 AC021593.1 ARFGEF2 ARHGAP1 ARL17A C17orf81 C6orf167 CCDC3 CCDC65 FAM171A1 FOXO3 IMMP1L KANSL1 PFDN1 PIAS4 PM20D1 PTBP2 REEP5 RMI1 RP5-921G16.1 SETD2 SH2B3 SPATS2L TPGS2 TRPT1 ZMIZ2
Verbal and Numeric Reasoning (VNR) 4.05 5 3 6.7 0.36 5.6e-01 ARFGEF2 ARHGAP1 CCDC65 FOXO3 PFDN1
Breast Cancer 0.86 1 0 0.0 0.00 1.0e+00 C17orf81
Prostate Cancer 2.01 1 0 0.0 0.00 1.0e+00 PM20D1
Bipolar Disorder (2011) 2.86 1 0 0.0 0.00 1.0e+00 CCDC65
Coronary Artery Disease (CAD) 1.88 1 0 0.0 0.00 1.0e+00 SH2B3
LDL Cholesterol 1.64 1 0 0.0 0.00 1.0e+00 SH2B3
Primary Biliary Cirrhosis 1.71 1 1 2.2 0.00 1.0e+00 SH2B3
Rheumatoid Arthritis 1.41 1 0 0.0 0.00 1.0e+00 SH2B3
Schizophrenia (2014) 2.04 2 0 0.0 0.00 1.0e+00 ARHGAP1 PTBP2
Blood Eosinophil Count 7.62 3 2 4.4 0.00 1.0e+00 C17orf81 RMI1 SH2B3
Blood Platelet Count 1.93 5 5 11.1 -0.03 9.6e-01 ARL17A KANSL1 RMI1 SH2B3 TRPT1
Blood Red Count 2.68 7 4 8.9 0.05 9.1e-01 AC009228.1 ARFGEF2 ARL17A IMMP1L PIAS4 SH2B3 SPATS2L
Blood White Count 4.85 6 4 8.9 0.75 8.4e-02 AC009228.1 C6orf167 PIAS4 RMI1 SETD2 SH2B3
Heel T-Score 2.00 8 5 11.1 0.49 2.1e-01 ARHGAP1 C17orf81 CCDC65 IMMP1L PIAS4 REEP5 RMI1 SETD2
BMI 2.61 10 5 11.1 -0.01 9.7e-01 ARFGEF2 C17orf81 C6orf167 FOXO3 PFDN1 PIAS4 PM20D1 PTBP2 REEP5 TRPT1
Height 1.99 14 11 24.4 -0.24 4.1e-01 AC009228.1 ARFGEF2 ARL17A CCDC3 FOXO3 IMMP1L KANSL1 PIAS4 PM20D1 REEP5 RMI1 RP5-921G16.1 SH2B3 ZMIZ2
Waist Hip Ratio (WHR) 1.34 3 2 4.4 0.00 1.0e+00 ARL17A KANSL1 SETD2
Systolic Blood Pressure 3.61 6 3 6.7 0.51 3.0e-01 ARFGEF2 ARL17A C17orf81 FOXO3 SH2B3 SPATS2L
Smoking Status 1.50 1 0 0.0 0.00 1.0e+00 KANSL1
Allergy or Eczema 1.12 1 0 0.0 0.00 1.0e+00 SH2B3
Cardiovascular Disease 2.76 3 1 2.2 0.00 1.0e+00 C17orf81 C6orf167 SH2B3
Hypothyroidism (self reported) 5.31 1 1 2.2 0.00 1.0e+00 SH2B3
Type 2 Diabetes (T2D) (2018) 1.33 1 0 0.0 0.00 1.0e+00 SH2B3
Lung FEV1/FVC ratio 1.49 4 2 4.4 -0.71 2.9e-01 ARFGEF2 C17orf81 FOXO3 PM20D1
Lung FVC 2.03 8 4 8.9 -0.39 3.4e-01 ARFGEF2 ARL17A C17orf81 FOXO3 KANSL1 RMI1 SH2B3 SPATS2L
Neuroticism 1.99 3 0 0.0 0.00 1.0e+00 ARHGAP1 KANSL1 PFDN1
Chronotype (morning person) 1.86 1 1 2.2 0.00 1.0e+00 RMI1
Hair Pigment 0.28 5 3 6.7 -0.97 7.7e-03 ARL17A CCDC65 FOXO3 PM20D1 SH2B3
Tanning 0.25 2 0 0.0 0.00 1.0e+00 PFDN1 SH2B3
Hand grip strength (left) 2.57 1 1 2.2 0.00 1.0e+00 PM20D1
Number of treatments/medications taken 2.33 1 1 2.2 0.00 1.0e+00 SH2B3
Sensitivity / hurt feelings 1.51 1 0 0.0 0.00 1.0e+00 RMI1
Frequency of depressed mood in last 2 weeks 2.23 2 0 0.0 0.00 1.0e+00 ARFGEF2 ARHGAP1
Hearing difficulty/problems: Yes 1.58 1 0 0.0 0.00 1.0e+00 C17orf81
Relative age of first facial hair 1.48 1 0 0.0 0.00 1.0e+00 FOXO3
Systolic blood pressure, automated reading 2.48 3 1 2.2 0.00 1.0e+00 ARL17A C17orf81 SH2B3
Vitamin and mineral supplements 2.05 1 0 0.0 0.00 1.0e+00 SETD2
Impedance of leg (right) 1.53 4 1 2.2 0.40 6.0e-01 CCDC65 FOXO3 PM20D1 SPATS2L
Leg fat-free mass (left) 2.39 7 4 8.9 -0.79 3.3e-02 FOXO3 KANSL1 PM20D1 PTBP2 REEP5 SH2B3 ZMIZ2
Trunk fat percentage 2.39 8 2 4.4 -0.56 1.5e-01 ARL17A C6orf167 FOXO3 KANSL1 PIAS4 PTBP2 RMI1 TRPT1
Hand grip strength (right) 2.31 2 1 2.2 0.00 1.0e+00 ARFGEF2 PM20D1
Fed-up feelings 2.35 3 1 2.2 0.00 1.0e+00 ARHGAP1 C17orf81 SH2B3
Relative age voice broke 1.46 1 0 0.0 0.00 1.0e+00 FOXO3
Taking other prescription medications 2.20 1 1 2.2 0.00 1.0e+00 SH2B3
Age when periods started (menarche) 2.02 2 1 2.2 0.00 1.0e+00 CCDC65 FOXO3
Heel bone mineral density (BMD) T-score, automated (left) 1.49 1 1 2.2 0.00 1.0e+00 ARHGAP1
High blood pressure 2.64 3 1 2.2 0.00 1.0e+00 C17orf81 PIAS4 SH2B3
Medication: Atenolol 2.25 1 1 2.2 0.00 1.0e+00 SH2B3
Medication: Levothyroxine sodium 4.70 1 1 2.2 0.00 1.0e+00 SH2B3
Sitting height 2.07 6 5 11.1 0.20 7.1e-01 AC009228.1 ARFGEF2 CCDC3 FOXO3 PM20D1 REEP5
Body mass index (BMI) 2.23 6 2 4.4 0.00 9.9e-01 C6orf167 FOXO3 PFDN1 PIAS4 PTBP2 TRPT1
Impedance of leg (left) 1.52 4 0 0.0 0.26 7.4e-01 CCDC65 PFDN1 PM20D1 SPATS2L
Leg predicted mass (left) 2.41 7 4 8.9 -0.79 3.3e-02 FOXO3 KANSL1 PM20D1 PTBP2 REEP5 SH2B3 ZMIZ2
Trunk fat mass 2.60 10 2 4.4 -0.38 2.8e-01 ARL17A C6orf167 FOXO3 KANSL1 PIAS4 PTBP2 REEP5 RMI1 TRPT1 ZMIZ2
Waist circumference 2.39 6 2 4.4 0.06 9.0e-01 C17orf81 C6orf167 FOXO3 KANSL1 PIAS4 REEP5
Past tobacco smoking 1.97 1 0 0.0 0.00 1.0e+00 SH2B3
Alcohol usually taken with meals 1.88 1 0 0.0 0.00 1.0e+00 RMI1
Hearing difficulty/problems with background noise 2.19 2 0 0.0 0.00 1.0e+00 ARHGAP1 PM20D1
Forced vital capacity (FVC) 2.63 6 3 6.7 -0.73 1.0e-01 ARFGEF2 ARL17A C17orf81 KANSL1 PIAS4 SPATS2L
Heel bone mineral density (BMD) T-score, automated (right) 1.64 1 1 2.2 0.00 1.0e+00 ARHGAP1
Qualifications: None of the above 2.93 4 0 0.0 0.56 4.4e-01 ARFGEF2 C6orf167 FOXO3 SPATS2L
Heart attack 1.85 1 0 0.0 0.00 1.0e+00 SH2B3
Medication: Simvastatin 1.35 1 0 0.0 0.00 1.0e+00 PIAS4
Fluid intelligence score 2.76 4 1 2.2 0.23 7.7e-01 ARFGEF2 ARHGAP1 FOXO3 PFDN1
Illnesses of siblings 2.11 1 0 0.0 0.00 1.0e+00 SH2B3
Neuroticism score 1.71 1 0 0.0 0.00 1.0e+00 ARHGAP1
Weight 2.59 8 5 11.1 -0.77 2.5e-02 FOXO3 KANSL1 PM20D1 PTBP2 REEP5 SH2B3 TRPT1 ZMIZ2
Impedance of arm (right) 2.77 9 4 8.9 0.06 8.7e-01 ARL17A CCDC65 FOXO3 IMMP1L PFDN1 PM20D1 REEP5 RMI1 SH2B3
Arm fat percentage (right) 2.40 8 2 4.4 -0.66 7.3e-02 ARFGEF2 ARL17A C6orf167 FOXO3 KANSL1 PIAS4 PTBP2 TRPT1
Trunk fat-free mass 2.37 7 4 8.9 -0.50 2.5e-01 ARFGEF2 FOXO3 KANSL1 PM20D1 REEP5 SH2B3 ZMIZ2
Hip circumference 2.26 7 1 2.2 -0.48 2.8e-01 C17orf81 FOXO3 PIAS4 PTBP2 SH2B3 TRPT1 ZMIZ2
Father's age at death 1.98 1 1 2.2 0.00 1.0e+00 SH2B3
Frequency of tiredness / lethargy in last 2 weeks 2.34 2 0 0.0 0.00 1.0e+00 ARFGEF2 ARHGAP1
Number of live births 1.51 2 0 0.0 0.00 1.0e+00 AC021593.1 TRPT1
Forced expiratory volume in 1-second (FEV1) 2.32 4 3 6.7 -0.76 2.4e-01 ARFGEF2 ARL17A KANSL1 PIAS4
Happiness 1.46 1 0 0.0 0.00 1.0e+00 ARFGEF2
Qualifications: A levels/AS levels or equivalent 2.52 3 0 0.0 0.00 1.0e+00 ARFGEF2 C6orf167 SPATS2L
Forced expiratory volume in 1-second (FEV1), Best measure 1.86 4 3 6.7 -0.72 2.8e-01 ARFGEF2 ARL17A KANSL1 PIAS4
Impedance of arm (left) 2.60 8 3 6.7 0.26 5.4e-01 ARL17A FOXO3 IMMP1L PFDN1 REEP5 RMI1 SH2B3 SPATS2L
Arm fat mass (right) 2.64 9 3 6.7 -0.42 2.6e-01 ARL17A C6orf167 FOXO3 KANSL1 PIAS4 PTBP2 REEP5 TRPT1 ZMIZ2
Trunk predicted mass 2.40 7 4 8.9 -0.50 2.5e-01 ARFGEF2 FOXO3 KANSL1 PM20D1 REEP5 SH2B3 ZMIZ2
Standing height 2.06 12 9 20.0 -0.35 2.7e-01 AC009228.1 ARFGEF2 ARL17A CCDC3 FOXO3 KANSL1 PIAS4 PM20D1 REEP5 RMI1 SH2B3 ZMIZ2
Tense / 'highly strung' 1.59 1 0 0.0 0.00 1.0e+00 PM20D1
Hair/balding pattern: Pattern 4 1.40 1 0 0.0 0.00 1.0e+00 RMI1
Birth weight of first child 3.13 3 1 2.2 0.00 1.0e+00 ARFGEF2 C17orf81 SH2B3
Peak expiratory flow (PEF) 2.99 2 1 2.2 0.00 1.0e+00 FOXO3 PM20D1
Pulse wave reflection index 1.72 1 0 0.0 0.00 1.0e+00 RMI1
Qualifications: O levels/GCSEs or equivalent 2.81 4 0 0.0 -0.25 7.5e-01 ARFGEF2 C6orf167 PIAS4 RMI1
Medication for cholesterol, blood pressure or diabetes 1.59 1 1 2.2 0.00 1.0e+00 SH2B3
Gout (self-reported) 1.49 1 0 0.0 0.00 1.0e+00 SH2B3
Hypothyroidism/myxoedema (self-reported) 4.53 1 1 2.2 0.00 1.0e+00 SH2B3
Birth weight 4.48 2 2 4.4 0.00 1.0e+00 C17orf81 SH2B3
High blood pressure (siblings) 1.53 1 0 0.0 0.00 1.0e+00 SH2B3
Forced vital capacity (FVC), Best measure 2.40 4 3 6.7 -0.69 3.1e-01 ARFGEF2 ARL17A KANSL1 PIAS4
Body fat percentage 2.36 8 1 2.2 -0.61 1.1e-01 ARFGEF2 ARL17A C6orf167 FOXO3 KANSL1 PIAS4 PTBP2 TRPT1
Leg fat percentage (right) 2.12 6 1 2.2 -0.39 4.4e-01 ARFGEF2 C6orf167 FOXO3 PIAS4 PTBP2 TRPT1
Arm fat-free mass (right) 2.46 6 4 8.9 -0.74 9.2e-02 FOXO3 PM20D1 PTBP2 REEP5 SH2B3 ZMIZ2
Comparative body size at age 10 2.48 4 2 4.4 -0.60 4.0e-01 ARL17A CCDC65 KANSL1 PM20D1
Worry too long after embarrassment 1.54 1 1 2.2 0.00 1.0e+00 PFDN1
Seen a psychiatrist for nerves, anxiety, tension or depression 2.03 1 0 0.0 0.00 1.0e+00 PM20D1
Qualifications: College or University degree 2.34 5 2 4.4 -0.15 8.1e-01 ARFGEF2 C6orf167 FOXO3 PFDN1 SPATS2L
Medication: Blood pressure 2.21 3 1 2.2 0.00 1.0e+00 C17orf81 PIAS4 SH2B3
Medication: Allopurinol 1.62 1 0 0.0 0.00 1.0e+00 SH2B3
Whole body fat mass 2.54 8 3 6.7 -0.39 3.4e-01 ARL17A C6orf167 FOXO3 KANSL1 PIAS4 PTBP2 REEP5 TRPT1
Leg fat mass (right) 2.46 7 2 4.4 -0.14 7.6e-01 C6orf167 FOXO3 KANSL1 PIAS4 PTBP2 REEP5 TRPT1
Arm predicted mass (right) 2.47 5 4 8.9 -0.72 1.7e-01 FOXO3 PM20D1 REEP5 SH2B3 ZMIZ2
Pulse rate, automated reading 2.46 5 1 2.2 -0.71 1.8e-01 CCDC65 PIAS4 PM20D1 SPATS2L TRPT1
Alcohol intake frequency. 1.10 1 0 0.0 0.00 1.0e+00 AC009228.1
Comparative height size at age 10 2.15 10 5 11.1 -0.37 2.9e-01 ARFGEF2 ARL17A CCDC3 FOXO3 KANSL1 PIAS4 PM20D1 REEP5 RMI1 SH2B3
Suffer from 'nerves' 2.35 1 0 0.0 0.00 1.0e+00 ARHGAP1
Overall health rating 1.10 1 0 0.0 0.00 1.0e+00 SPATS2L
Medication: Aspirin 1.48 1 0 0.0 0.00 1.0e+00 SH2B3
Supplements: Vitamin C 1.58 1 0 0.0 0.00 1.0e+00 RMI1
Hypertension (Self-reported) 2.58 3 1 2.2 0.00 1.0e+00 C17orf81 PIAS4 SH2B3
Illnesses of father: Heart disease 2.02 1 0 0.0 0.00 1.0e+00 SH2B3
Smoking status: Previous 2.17 1 0 0.0 0.00 1.0e+00 SH2B3
Whole body fat-free mass 2.43 8 4 8.9 -0.56 1.5e-01 ARFGEF2 FOXO3 KANSL1 PM20D1 PTBP2 REEP5 SH2B3 ZMIZ2
Leg fat-free mass (right) 2.31 7 2 4.4 -0.81 2.8e-02 FOXO3 KANSL1 PM20D1 PTBP2 REEP5 SH2B3 ZMIZ2
Arm fat percentage (left) 2.26 8 2 4.4 -0.63 9.1e-02 ARFGEF2 ARL17A C6orf167 FOXO3 KANSL1 PIAS4 PTBP2 TRPT1
Handedness (chirality/laterality): Left-handed 1.83 2 0 0.0 0.00 1.0e+00 ARL17A KANSL1
Loneliness, isolation 2.85 2 1 2.2 0.00 1.0e+00 ARFGEF2 SH2B3
Qualifications: nursing, teaching 1.60 1 0 0.0 0.00 1.0e+00 RMI1
Mouth/teeth dental problems: Mouth ulcers 1.27 1 0 0.0 0.00 1.0e+00 SH2B3
Medication for cholesterol 1.78 1 1 2.2 0.00 1.0e+00 SH2B3
Illnesses of father: None of the above (group 1) 2.79 3 0 0.0 0.00 1.0e+00 PIAS4 PM20D1 SH2B3
Whole body water mass 2.43 8 4 8.9 -0.56 1.5e-01 ARFGEF2 FOXO3 KANSL1 PM20D1 PTBP2 REEP5 SH2B3 ZMIZ2
Leg predicted mass (right) 2.31 8 2 4.4 -0.59 1.3e-01 AC009228.1 FOXO3 KANSL1 PM20D1 PTBP2 REEP5 SH2B3 ZMIZ2
Arm fat mass (left) 2.52 9 2 4.4 -0.42 2.6e-01 ARL17A C6orf167 FOXO3 KANSL1 PIAS4 PTBP2 REEP5 TRPT1 ZMIZ2
Number of self-reported non-cancer illnesses 2.38 1 1 2.2 0.00 1.0e+00 SH2B3
Guilty feelings 1.60 1 0 0.0 0.00 1.0e+00 PFDN1
Medication: Blood pressure 2.41 1 1 2.2 0.00 1.0e+00 SH2B3
Medication: Bendroflumethiazide 1.74 1 0 0.0 0.00 1.0e+00 SH2B3
Medication: Lisinopril 2.08 1 0 0.0 0.00 1.0e+00 SH2B3
Illnesses of father: High blood pressure 1.61 1 0 0.0 0.00 1.0e+00 SH2B3
Ever smoked 1.42 1 0 0.0 0.00 1.0e+00 SH2B3
Basal metabolic rate 2.53 7 4 8.9 -0.78 3.9e-02 FOXO3 KANSL1 PM20D1 PTBP2 REEP5 SH2B3 ZMIZ2
Leg fat percentage (left) 2.05 5 1 2.2 -0.32 6.0e-01 ARFGEF2 C6orf167 FOXO3 PIAS4 PTBP2
Arm fat-free mass (left) 2.58 7 4 8.9 -0.76 4.9e-02 FOXO3 KANSL1 PM20D1 PTBP2 REEP5 SH2B3 ZMIZ2
Number of operations (self-reported) 1.60 1 0 0.0 0.00 1.0e+00 FAM171A1
Diastolic blood pressure, automated reading 3.41 2 1 2.2 0.00 1.0e+00 C17orf81 SH2B3
Ever depressed for a whole week 1.33 1 0 0.0 0.00 1.0e+00 ARFGEF2
Vascular/heart problems diagnosed by doctor 2.71 3 1 2.2 0.00 1.0e+00 C17orf81 PIAS4 SH2B3
Pain experienced in last month 1.58 1 0 0.0 0.00 1.0e+00 SH2B3
Heart attack/myocardial infarction (self-reported) 1.81 1 0 0.0 0.00 1.0e+00 SH2B3
Impedance of whole body 2.17 8 4 8.9 0.05 9.1e-01 ARL17A CCDC65 FOXO3 IMMP1L PFDN1 PM20D1 RMI1 SPATS2L
Leg fat mass (left) 2.45 7 2 4.4 -0.13 7.8e-01 C6orf167 FOXO3 KANSL1 PIAS4 PTBP2 REEP5 TRPT1
Arm predicted mass (left) 2.55 7 4 8.9 -0.76 4.7e-02 FOXO3 KANSL1 PM20D1 PTBP2 REEP5 SH2B3 ZMIZ2

Associations by panel

study tissue # hits % hits/tests avg chisq
GTEx Adipose Subcutaneous 9 0.258 1.9
GTEx Adipose Visceral Omentum 4 0.196 2.0
GTEx Adrenal Gland 4 0.275 2.1
GTEx Artery Aorta 8 0.269 2.0
GTEx Artery Coronary 2 0.169 2.0
GTEx Artery Tibial 9 0.239 2.0
GTEx Brain Caudate basal ganglia 1 0.109 1.9
GTEx Brain Cerebellar Hemisphere 3 0.201 2.0
GTEx Brain Cerebellum 4 0.202 2.0
GTEx Brain Cortex 3 0.290 2.0
GTEx Brain Frontal Cortex BA9 3 0.325 2.1
GTEx Brain Hippocampus 1 0.191 2.0
GTEx Brain Hypothalamus 1 0.169 1.9
GTEx Brain Nucleus accumbens basal ganglia 4 0.462 2.1
GTEx Brain Putamen basal ganglia 1 0.160 2.1
GTEx Breast Mammary Tissue 6 0.304 2.0
GTEx Breast Mammary Tissue (Male) 2 0.168 1.9
GTEx Breast Mammary Tissue (Female) 2 0.122 1.9
GTEx Cells EBV-transformed lymphocytes 4 0.281 1.9
GTEx Cells Transformed fibroblasts 5 0.119 1.9
GTEx Colon Sigmoid 2 0.137 2.1
GTEx Colon Transverse 6 0.291 2.0
GTEx Esophagus Gastroesophageal Junction 5 0.346 2.1
GTEx Esophagus Mucosa 9 0.271 2.0
GTEx Esophagus Muscularis 9 0.278 2.1
GTEx Heart Atrial Appendage 3 0.190 2.0
GTEx Heart Left Ventricle 3 0.196 2.1
GTEx Liver 5 0.697 2.2
GTEx Lung 7 0.244 2.0
GTEx Muscle Skeletal 8 0.277 2.1
GTEx Nerve Tibial 13 0.301 2.0
GTEx Ovary 4 0.441 2.0
GTEx Pancreas 5 0.306 2.0
GTEx Pituitary 6 0.538 2.3
GTEx Prostate 4 0.479 1.9
GTEx Skin Not Sun Exposed Suprapubic 9 0.366 2.0
GTEx Skin Sun Exposed Lower leg 12 0.330 2.1
GTEx Small Intestine Terminal Ileum 0 0.000 1.9
GTEx Spleen 3 0.213 2.0
GTEx Stomach 4 0.275 1.9
GTEx Testis 11 0.349 2.1
GTEx Thyroid 10 0.250 2.0
GTEx Uterus 1 0.176 1.7
GTEx Vagina 0 0.000 1.9
GTEx Whole Blood 1 0.050 2.0
METSIM Adipose 7 0.152 1.9
NTR Blood 1 0.042 1.7
ROSMAP Brain Pre-frontal Cortex 5 0.114 2.0
YFS Blood 8 0.173 1.8
CommonMind Brain Pre-frontal Cortex 10 0.186 1.9
The Cancer Genome Atlas Bladder Urothelial Carcinoma 2 0.121 1.8
The Cancer Genome Atlas Breast Invasive Carcinoma 4 0.091 1.8
The Cancer Genome Atlas Cervical Squamous Cell Carcinoma 2 0.182 1.7
The Cancer Genome Atlas Colon Adenocarcinoma 3 0.145 1.8
The Cancer Genome Atlas Esophageal Carcinoma 0 0.000 1.6
The Cancer Genome Atlas Glioblastoma Multiforme 0 0.000 1.8
The Cancer Genome Atlas Head and Neck Squamous Cell Carcinoma 3 0.110 1.9
The Cancer Genome Atlas Kidney Renal Clear Cell Carcinoma 7 0.171 1.8
The Cancer Genome Atlas Kidney Renal Papillary Cell Carcinoma 2 0.098 1.8
The Cancer Genome Atlas Brain Lower Grade Glioma 5 0.116 1.8
The Cancer Genome Atlas Liver Hepatocellular Carcinoma 0 0.000 1.9
The Cancer Genome Atlas Lung Adenocarcinoma 3 0.102 1.8
The Cancer Genome Atlas Lung Squamous Cell Carcinoma 2 0.080 1.7
The Cancer Genome Atlas Ovarian Serous Cystadenocarcinoma 3 0.188 1.8
The Cancer Genome Atlas Pancreatic Adenocarcinoma 2 0.120 1.8
The Cancer Genome Atlas Pheochromocytoma and Paraganglioma 2 0.151 1.8
The Cancer Genome Atlas Prostate Adenocarcinoma 5 0.108 1.8
The Cancer Genome Atlas Rectum Adenocarcinoma 0 0.000 1.8
The Cancer Genome Atlas Soft Tissue Sarcoma 3 0.281 1.9
The Cancer Genome Atlas Skin Cutaneous Melanoma 1 0.187 1.8
The Cancer Genome Atlas Stomach Adenocarcinoma 5 0.297 1.8
The Cancer Genome Atlas Testicular Germ Cell Tumors 4 0.313 1.9
The Cancer Genome Atlas Thyroid Carcinoma 6 0.116 1.8
The Cancer Genome Atlas Uterine Corpus Endometrial Carcinoma 1 0.197 2.1